Browsing by Subject "non-compliance"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Environmental Tobacco Smoke Exposure in Children: Compliance with a Home Smoking Ban Among Texas Households(2007-12-01) Rodriguez, Lori A.; Cardarelli, Kathryn; Ramisetty-Mikler, Suhasini; Lin, Yu-ShengRodriguez, Lori A., Environmental Tobacco Smoke Exposure in Children: Compliance With a Home Smoking Ban Among Texas Households. Master of Public Health (Epidemiology), December, 2007, 72 pp., 10 tables, bibliography, 75 titles. This general population study explores characteristics influencing non-compliance with a home smoking ban among Texas households with children, particularly those with asthmatic children. Over 17% of adults reported non-compliance, with the highest rate in African Americans. Adults who currently smoke (25%) had higher reports of having an asthmatic child in the household and were more likely to not comply. Child asthma status was not a significant predictor of non-compliance; however, African Americans with no asthmatic children were more likely than African Americans with an asthmatic child to not comply. The role of race/ethnicity should be further investigated to improve interventions and home smoking bans should continue to be promoted in an effort to reduce environmental tobacco smoke exposure.Item Impact of Intraocular Pressure Maintenance on Sight Preservation(2002-05-01) Ratliff, Marla D.; Susan Brown; Kristine A. Lykens; Claudia S. CogginRatliff, Marla D., Impact of Intraocular Pressure Maintenance on Sight Preservation. Master of Public Health (Health Services Research), May 2002, 35 pp., 3 tables, 1 figure, 40 titles. Purpose: The objective of the study was to review diurnal IOP control and its impact on sight preservation. Methods: This is a retrospective study used in patients with elevated IOP. Patient IOPs were measured every 4 hours over a 24-hour period. Qualified patients provided open label TRAVATAN to dose once a day for 2 weeks. Following 2 weeks of dosing, IOP measurements were taken every 4 hours for 36 hours. Additional IOP measurements were taken at 60 and 84 hours after the last dose of TRAVATAN. Results: The IOP changes from baseline were statistically significant (p≤0.0001) at all time points out to 36 hours. Even without additional dosing, substantial IOP reductions (6mm Hg) were maintained out to 84 hours. Conclusions: Use of TRAVATAN may have less impact on IOP maintenance due to non-compliance and missed doses. This could help prevent glaucomatous loss and preserve sight.